<?xml version="1.0" encoding="UTF-8"?>
<p>Prior preclinical doses used for gene transfer via AAV have ranged from 3 x 10
 <sup>11</sup>–10
 <sup>14</sup> gc/animal in macaques.[
 <xref rid="ppat.1007395.ref026" ref-type="bibr">26</xref>–
 <xref rid="ppat.1007395.ref030" ref-type="bibr">30</xref>] Human clinical trials deliver comparable doses at 1.6 x 1013–4 x 10
 <sup>14</sup> gc/subject based on a 80 kg subject.[
 <xref rid="ppat.1007395.ref012" ref-type="bibr">12</xref>,
 <xref rid="ppat.1007395.ref014" ref-type="bibr">14</xref>,
 <xref rid="ppat.1007395.ref022" ref-type="bibr">22</xref>,
 <xref rid="ppat.1007395.ref023" ref-type="bibr">23</xref>,
 <xref rid="ppat.1007395.ref040" ref-type="bibr">40</xref>,
 <xref rid="ppat.1007395.ref043" ref-type="bibr">43</xref>] Stroes et al. administered 8 x 10
 <sup>12</sup> and 2.4 x 10
 <sup>13</sup> gc/subject (based on 80 kg/subject) of AAV1 to deliver a lipoprotein lipase in 40 or 60 injections respectively.[
 <xref rid="ppat.1007395.ref043" ref-type="bibr">43</xref>] These authors demonstrated persistent serum lipase activity up to 31 months, supporting the proposed dose spreading. Conversely, Manno et al. administered hF.IX via AAV2 at 1.4 x 10
 <sup>13</sup>–1.3 x 10
 <sup>14</sup> gc/subject in 10–20, 30–50 or 80–90 shots, but found low serum transgene accumulation.[
 <xref rid="ppat.1007395.ref040" ref-type="bibr">40</xref>]
</p>
